A recent study investigated Rambazole, a novel retinoic acid metabolism-blocking agent (RAMBA), revealing promising results for acne treatment. The study found that 94% of participants with moderate-to-severe acne, who received a daily 1mg oral dose of Rambazole for 12 weeks, experienced a reduction of over 50% in their total acne lesion count. Furthermore, 35% of these participants were classified as “cleared or almost cleared.”
These findings suggest a potential future for this medication. Barrier Therapeutics, Inc. has previously reported positive Phase 2a data for both an oral formulation of Rambazole in treating moderate to severe acne and positive biological activity data for a topical formulation.
Experts state that a reduction of over 90% in total lesion count is the benchmark for being considered “cleared or almost cleared.” The study indicated that both inflammatory and non-inflammatory lesions responded well to the treatment. Importantly, no serious side effects were attributed to the Rambazole treatment. The most common side effects reported were mild dryness of the skin and lips.
Dr. Geert Cauwenbergh, Chairman and CEO of Barrier Therapeutics, Inc., commented, “These encouraging Phase 2a results indicate that oral Rambazole demonstrates activity against moderate to severe inflammatory acne. Depending on the outcomes of future, larger-scale clinical trials, this drug could potentially address the need for safe and effective oral treatments for moderate and severe acne. These results also build upon our previously announced encouraging clinical data for oral Rambazole in treating psoriasis.”